Charles River Laboratories Inte
Stocks
Walt Disney Company (The)
Stocks
Charles River Laboratories vs Walt Disney Company: A Performance-Focused Stock Comparison
Last updated: June 8, 2026
Summary
Charles River Laboratories, operating in the healthcare diagnostics sector, exhibits a challenging profitability profile with a negative EPS and moderate market cap, while Walt Disney, a leader in entertainment, demonstrates robust earnings, a high market valuation, and strong profit margins. This comparison highlights their distinct performance metrics and investment potential based on recent financial data.
Key Differences at a Glance
| Aspect | Charles River Laboratories Inte | Walt Disney Company (The) | Winner |
|---|---|---|---|
| Earnings Per Share (EPS) | -3.72 | 6.25 | Walt Disney Company (The) |
| Market Capitalization | 8.73 billion USD | 173.15 billion USD | Walt Disney Company (The) |
| Profit Margin | -0.04585 | 0.1154 | Walt Disney Company (The) |
| Price-to-Earnings (PE) Ratio | N/A (negative EPS) | 15.95 | Walt Disney Company (The) |
| Revenue | 4.03 billion USD | 97.26 billion USD | Walt Disney Company (The) |
Earnings Per Share (EPS): Disney's positive EPS of 6.25 contrasts sharply with Charles River's negative EPS of -3.72, indicating Disney's profitability and stronger earnings generation capability.
Market Capitalization: Walt Disney's market cap far exceeds Charles River's, reflecting its commanding position in the entertainment industry and greater investor confidence.
Profit Margin: Disney's profit margin of 11.54% demonstrates effective cost management and profitability, whereas Charles River's negative margin indicates operational challenges.
Price-to-Earnings (PE) Ratio: Disney's PE ratio of 15.95 suggests a more attractive valuation given its positive earnings, while Charles River's negative EPS renders its PE ratio non-informative and indicates weaker valuation metrics.
Revenue: Disney's revenue vastly surpasses Charles River's, reflecting its extensive consumer base and diversified revenue streams across media networks, theme parks, and licensing.
Detailed Analysis
Charles River Laboratories operates within the healthcare diagnostics and research industry, with a revenue of approximately $4.03 billion and a market capitalization of about $8.73 billion. Despite its significant size, the company reports a negative EPS of -3.72, indicating recent profitability challenges, possibly due to increased research costs or operational inefficiencies. Its profit margin of -4.6% underscores operational losses, and its forward PE ratio of roughly 14.73 suggests investors expect modest earnings growth, but the current negative earnings cloud valuation metrics.
In contrast, Walt Disney Company stands as a global entertainment giant with a revenue of nearly $97.3 billion and a market cap exceeding $173 billion. Disney's EPS of 6.25 reflects consistent profitability, supported by a profit margin of approximately 11.5%. Its PE ratio of around 15.95 is attractive given its earnings, and the company maintains a dividend yield of 1.5%, appealing to income-focused investors. Disney's broad revenue streams from media, parks, and licensing contribute to its financial stability and growth potential.
From a performance standpoint, Disney clearly outperforms Charles River in terms of profitability, valuation, and revenue generation. The company's high revenue and positive earnings signal resilience and market dominance, whereas Charles River's negative EPS and slim profit margins point to ongoing operational risks. However, Charles River's focus on research and diagnostics offers niche growth opportunities, especially if the healthcare industry continues to expand, but it currently lags in key performance metrics.
Overall, Disney's financial strength and profitability make it a more attractive candidate for investors seeking stable returns and growth, whereas Charles River may appeal to those interested in the healthcare diagnostics sector with a higher risk profile and potential for future recovery as market conditions improve.
Verdict
Walt Disney Company exhibits stronger overall performance metrics with positive earnings, higher revenue, and better profit margins, making it the preferable choice for investors prioritizing profitability and market valuation. However, Charles River Laboratories could be attractive for specialized healthcare investors willing to accept short-term operational challenges, with potential upside in the diagnostics research sector once profitability improves.
Who Should Choose What
Choose Charles River Laboratories Inte if...
Investors seeking exposure to healthcare diagnostics and research sectors, with an interest in niche growth potential despite current profitability challenges.
Choose Walt Disney Company (The) if...
Investors looking for stability, consistent earnings, and diversification in the entertainment and media industry, with strong market valuation and dividend income.